Tags : Wuxi Biologics

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 15 – 19, 2021)

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Published: Mar 19, 2021 | Tags: Takeda, Collaborates, Anima, Discover, Develop, mRNA Translation Modulators, Neurological Diseases Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the Treatment of Pericarditis Published: Mar 19, 2021 | Tags: Kiniksa, Arcalyst (rilonacept), Receives, US, FDA, […]Read More

Biosimilars M&A

WuXi Biologics to Acquire Pfizer’s Biologics Manufacturing Facilities in China

Shots: WuXi Biologics signs an equity agreement with Pfizer to acquire its state-of-the-art biologics manufacturing facilities along with its labor force in Hangzhou, China. The transaction is expected to close in H1’21 The agreement will boost WuXi Biologics’ commercial DS & DP capabilities to address surging manufacturing demands The state-of-the-art 50,000 m2 facilities include DS […]Read More


Exelixis Signs an Exclusive License Agreement with WuXi Biologics to

Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel Exelixis get an exclusive license to the panel of mAb against an undisclosed oncology target for biologics applications Exelixis leverages WuXi Bio’s integrated technology platforms to develop […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (April 27 -May 01, 2020)

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis Published: Apr 30, 2020 | Tags: WuXi Biologics, Aravive, Collaborate, Develop, Novel, High-Affinity Bispecific Antibodies, Cancer,  Fibrosis  Novartis’ Enerzair Breezhaler (QVM149, IND/GLY/MF) Receives CHMP’s Recommendation for Approval as a Treatment for Uncontrolled Asthma Published: May 01, 2020 | Tags: Novartis, Enerzair, […]Read More


WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific

Shots: The collaboration leverages WuXi’s WuXiBody platform to develop high-affinity bispecific Ab targeting CCN2 for the treatment of cancer and fibrosis WuXi Biologics will be responsible for biologics discovery, process development, and manufacturing, whereas Aravive will be responsible for pre/ clinical development In 2018, Aravive and WuXi Biologics expanded their manufacturing collaboration for development and […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (February 24-28, 2020)

1. Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation Published: Feb 28, 2020 | Tags: Companion Medical, InPen Diabetes Management System, Receives, US, FDA, Approval, Fixed Dosing, Meal Estimation 2.  Takeda’s Vedolizumab SC Receives CHMP’s Positive Opinion as a Maintenance Therapy for Moderately to Severely Active […]Read More


WuXi Biologics and Vir Biotechnology Collaborate for the Global Development

Shots: The companies will jointly develop, manufacture & commercialize Vir’s Ab. WuXi Biologics will conduct cell-line development, process & formulation development and initial manufacturing for clinical development Following the regulatory approvals, Wuxi Biologics to get rights to commercialize therapies in Greater China while Vir retain WW commercial rights for the therapies The collaboration accelerates the […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More


Oxford BioTherapeutics Licenses WuXi Biologics’ WuXiBody Platform for Five Bispecific

Shots: Wuxi  to receive upfront, $450M milestone and royalties on sales from Oxford BioTherapeutics. Oxford to get rights for WuXi Biologics’ WuXiBody platform to develop and commercialize five Bispecific Abs for cancer The focus of the agreement is to develop cancer therapies by combining WuXiBody platform with PDL1 Ab with reduction in cost & risk rates WuXiBody platform is a bispecific […]Read More


I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more

Shots: I-Mab plans to license WuxiBody a proprietary platform from Wuxi for the development of three bispecific antibodies with focus on immuno-oncology and auto-immune This colloboration is the expansion of 2017 agreement between the companies which was intended for development and manufacturing of I-Mab pipeline products WuXiBody bispecifics have achieved 16g/L in cell culture titer, […]Read More